
Number of publications published per year by Llovet, Josep M.. (Source : PubMed)

Distribution of publications types for Llovet, Josep M.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
J. Hepatol.
2010;52;4

miRNA delivery: emerging therapy for hepatocellular carcinoma.
Gastroenterology
2010;138;3

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Semin. Liver Dis.
2010;30;1
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
Semin. Liver Dis.
2010;30;1
Two decades of advances in hepatocellular carcinoma research.
Semin. Liver Dis.
2010;30;1

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Annu. Rev. Med.
2010;61


Lymphotoxins: new targets for hepatocellular carcinoma.
Cancer Cell
2009;16;4

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
J. Hepatol.
2009;51;4

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Cancer Res.
2009;69;18
Accomplishments in 2008 in the management of hepatobiliary cancers.
Gastrointestinal cancer research : GCR
2009;3;5 Supplement 2
[ See timeline ] [ See all publications ]
means that Llovet, Josep M. has 53 papers cited a least 53 times - methodology
Barcelona-Clínic Liver Cancer Group, Liver Unit, Hospital Clínic, Barcelona, Spain.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.